International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com,
announced today that its wholly-owned subsidiary, Lifeline Skin Care,
Inc., in partnership with an experienced OTC drug licensed manufacturer
of cosmetic products, successfully manufactured its first scaled-up lots
of stem cell-based skin creams, confirming that these unique products
can be made in larger batch quantities and continue to meet Lifeline's
high quality standards. This marks an important milestone in proving
that two new technologies, the derivation of human parthenogenetic stem
cells, and the packaging and delivery of critical anti-aging
ingredients, including those derived from stem cells, can be scaled-up
into a level of production suitable to meet commercial levels of demand.
Lifeline Skin Care's product development scientists have combined human
parthenogenetic stem cell technology with the latest discoveries in skin
rejuvenation to create its unique day and night skin care creams. ISCO's
scientists were the first to intentionally create human parthenogenetic
stem cells from unfertilized human eggs, thus avoiding the ethical
concerns of harming a viable human embryo. ISCO's therapeutic research
team discovered that such cells had qualities that made them suitable
for skin care products, thus leading to the formation of ISCO's
wholly-owned subsidiary, Lifeline Skin Care. Valuable assistance from
ISCO's other wholly-owned subsidiary, Lifeline Cell Technology, allowed
the rapid transition and scale-up of a research-based discovery into a
quality-controlled commercial product. Lifeline Cell Technology is
staffed with experts in the manufacture and quality control of cell
based products.
According to Dr. Ruslan Semechkin, CEO of Lifeline Skin Care, "Although
it will be necessary to continue to develop new technologies to further
scale-up the production of our new skin care products, this first
successful manufacturing run proves that the team of ISCO's therapeutic
research scientists, in combination with Lifeline Skin Care's product
development expertise and Lifeline Cell Technology's manufacturing and
quality control expertise, has the ability to quickly develop and
commercialize new products using stem cell technologies."
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)
International Stem Cell Corporation is a California-based biotechnology
company focused on therapeutic and research products. ISCO's core
technology, parthenogenesis, results in creation of pluripotent human
stem cells from unfertilized oocytes (eggs). These proprietary cells
avoid ethical issues associated with use or destruction of viable human
embryos and, unlike most other major stem cell types, can be immune
matched and be a source of therapeutic cells with minimal rejection
after transplantation into hundreds of millions of individuals of
differing racial groups. ISCO also produces and markets specialized
cells and growth media for therapeutic research worldwide through its
subsidiary, Lifeline Cell Technology, and is developing a line of
cosmeceutical products via its subsidiary, Lifeline Skin Care. ISCO is
advancing novel human stem cell-based therapies where cells have been
proven to be efficacious but traditional small molecule and protein
therapeutics have not. More information is available on ISCO's website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS
Statements pertaining to anticipated developments, the potential
benefits of collaborations, affiliations, and other opportunities for
the company and its subsidiaries, along with other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products and the management of
collaborations, regulatory approvals, need and ability to obtain future
capital, application of capital resources among competing uses, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update forward-looking statements.
Key Words: Stem cells, parthenogenesis, biotechnology, skin care
International Stem Cell Corporation Kenneth C. Aldrich, Chairman 1-760-940-6383 kaldrich@intlstemcell.com or Lifeline
Skin Care, Inc. Ruslan Semechkin, Ph.D., President & CEO Vice
President, International Stem Cell Corporation ras@intlstemcell.com |